공고 • Jan 31
Rafarma Pharmaceuticals, Inc. Secures Joint Venture Agreement with the Pharmaceutical Industry Development Agency of Uzbekistan Rafarma Pharmaceuticals, Inc. announced its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan. Together the two organizations will produce medicines for use by public health institutions in the Republic of Uzbekistan. This will entail the acquisition of real property (10 hectares in the established Innovative Scientific Production Pharmaceutical Cluster known as “Tashkent Pharma Park”) and construction of a physical plant on the premises. Projected costs are currently at $82,000,000. Both parties will be tasked with developing a timetable for project completion and implementation (projected time table 2021-2025). Rafarma will supply experts in their respective fields, oversee construction, and supply necessary equipment. The Pharmaceutical Industry Development Agency will be responsible for obtaining the necessary registration and certification of all future medicines produced by the partnership, and negotiating contracts with the health sector of the Republic of Uzbekistan. 공고 • Dec 17
Vaccines Lab Sdn Bhd Enters Master Strategic Joint Venture Agreement with Rafarma Pharmaceuticals Inc Vaccines Lab Sdn Bhd enters Master Strategic Joint Venture agreement with Rafarma Pharmaceuticals Inc. 공고 • Dec 02
Rafarma Pharmaceuticals, Inc. Signs a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia Rafarma Pharmaceuticals, Inc. has signed a Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia. Under the terms of the agreement, Rafarma and Vaccines Lab with create a new jointly-operated vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines to combat several viruses. The joint venture will combine the expertise of Vaccines Lab and RAFARMA with its PJSC Kraspharma (OJSC Krasfarma) and R. & D. Biocogency Laboratories Inc. Rafarma plans to continue to aggressively pursue vaccine development with joint venture partners worldwide. 공고 • Oct 20
R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA). R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group.
R. & D. Biocogency Laboratories Inc. Ltd. completed the acquisition of an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on October 19, 2020. 공고 • Sep 19
Rafarma Pharmaceuticals, Inc. Appoints Ilia Shpurov as Chairman of the Board Rafarma Pharmaceuticals, Inc. announced the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs. Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability. 공고 • Aug 06
R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA). R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements.